CDNA Stock Analysis: Buy, Sell, or Hold?
CDNA - CareDx, Inc.
$43.71
5.61 (14.72%)
▲
5d:
+17.69%
30d:
+49.44%
90d:
+110.04%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CDNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CDNA is 16.3% above its trading range ($37.59). Market expects 22.1% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CDNA is 16.3% above its trading range ($37.59). Market expects 22.1% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$34.63
Based on 7.6% avg growth
INTRINSIC VALUE TODAY
$21.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CDNA is currently trading at $43.71, which is considered extended relative to its 30-day fair value range of $27.17 to $37.59. From a valuation perspective, the stock is trading at a premium (Forward PE: 38.5) compared to its historical average (21.2). At these levels, the market is pricing in 22.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $45.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.7% recently.
Market Sentiment: CDNA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $35.40. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $45.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.7% recently.
Market Sentiment: CDNA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $35.40. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.17 -
$37.59
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.7%
Protect Your Profits
CDNA is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+16.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.7%)
- BEARISH: Trading 19.0% above Wall St target ($35.40)
- NEUTRAL: Trading at premium valuation - market expects 22.1% growth which is achievable
- WARNING: Recommendation downgraded due to 16.3% overvaluation
Trading Range Analysis
30-Day Trading Range
$27.17 -
$37.59
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$35.01
Resistance Level
$45.00
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
38.54
Wall Street Target
$35.40
(-19.0%)
Revenue Growth (YoY)
39.0%
Profit Margin
-2.0%
Valuation Premium vs History
+22.1% premium
PE vs Historical
38.5 vs 21.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+22.1%
(market-implied from PE analysis)
1-Year Target
$53.37
(+22%)
2-Year Target
$65.16
(+49%)
3-Year Target
$79.57
(+82%)
3-Yr Target (if PE normalizes)
(PE: 39→21)
PE COMPRESSION
$43.76
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 38.5, Growth: 11.2%)
$60.06
(+37%)
Base:
(SPY PE: 20.7, Growth: 11.2%)
$32.30
(-26%)
Bear:
(PE: 17.6, Growth: 11.2%)
$27.46
(-37%)
Share & Embed Analysis
Last updated: August 02, 2026 12:45 PM ET
Data refreshes hourly during market hours. Next update: 1:45 PM
Data refreshes hourly during market hours. Next update: 1:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John Walter Hanna Jr
SELL
10282 shares
2026-04-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$630 | 53 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$188 | 61 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 52 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$283 | 59 HOLD |
Advanced CDNA Option Strategies
Professional options setups generated by AI based on today's CDNA price and gamma walls.
